1Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
2Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
3Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
Copyright © 2018 Korean Diabetes Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICTS OF INTEREST: Ahmed Iqbal and Peter Novodvorsky have no relevant conflicts of interest to disclose. Simon R. Heller received research grants from Medtronic UK Ltd. He has served on speaker panels for Sanofi Aventis, Eli Lilly, Takeda, NovoNordisk, and Astra Zeneca for which he has received remuneration. He has served on advisory panels or as a consultant for Boeringher Ingelheim, Novo Nordisk, Eli Lilly, and Takeda for which his institution has received remuneration.